Selegiline in Comparison with Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial
The DOI matches its OpenAlex record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The aim of this study was to examine the selegiline treatment compared to methylphenidate (MPH) in children and adolescents with attention deficit hyperactivity disorder (ADHD). METHOD: Forty subjects, aged 6-15 years, boys and girls, who were diagnosed as having ADHD, using the criteria of the Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV), were randomly assigned to receive either selegiline or MPH for 60 days. Treatment outcomes were assessed using the Attention Deficit Hyperactivity Scale (ADHS) administered at baseline and on days 14, 28, 42, and 60 following the commencement of treatment. Side effects were also rated. RESULTS: There were no significant differences between sex, age, weight, and ethnicity of participants in the 2 groups. Both groups showed a significant improvement over the 60 days of treatment resulting from the teachers' and parents' ADHS scores across the treatment. CONCLUSION: Following the trial, MPH did not effect greater mean improvement as a result of the parents' or teachers' ADHS scores than selegiline. Thus, selegiline appears to be effective and well tolerated for ADHD in children and adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Double-Blind, Placebo-Controlled Study of Single-Dose Amphetamine Formulations in ADHD
JAMES, R. S., SHARP, W. S., BASTAIN, T. M., LEE, P. P., WALTER, J. M., CZARNOLEWSKI, M., & CASTELLANOS, F. X. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200111000-00006 · Cited by 92
Cited by
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Finberg, J. P. M., & Rabey, J. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00340 · Cited by 432
Prince, J. B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.002 · Cited by 76
Drug and non-drug treatments of children with ADHD and tic disorders
Poncin, Y., Sukhodolsky, D. G., McGuire, J., & Scahill, L. (2007) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-007-1010-8 · Cited by 37
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder
Ashton, H., Gallagher, P., & Moore, B. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106061710 · Cited by 31
“These include monoamine oxidase inhibitors such as selegeline, noradrenaline reuptake inhibitors such as reboxetine and the stimulants pemoline and modafanil (Biederman and Spencer, 2004; Mohammadi et al., 2004; Brown et al., 2005; Fone and Nutt, 2005; Ratner et al., 2005).”
Background
Metadata
- Authors
- Mohammadi, M. R., Ghanizadeh, A. J., Alaghband‐Rad, J., Tehranidoost, M., Mesgarpour, B., & Soori, H.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- Mary Ann Liebert, Inc.
- Published
- 2004-09-01
- Volume
- 14
- Issue
- 3
- Pages
- 418-425
- ISSN
- 1044-5463 (ISSN-L)
- OpenAlex
- W2063593642
- Cited by
- 40
- References
- 1
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selegiline in Comparison with Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial. https://app.cochat.ai/papers/10.1089/1044546042389154
- The paper
- Mohammadi, M. R., Ghanizadeh, A. J., Alaghband‐Rad, J., Tehranidoost, M., Mesgarpour, B., & Soori, H. (2004). Selegiline in Comparison with Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/1044546042389154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.